Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × surufatinib × NET × Clear all

Phase

Phase 3 2 Phase 2 2 Phase 1/2 2 Phase 4 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Octreotide 4 Everolimus 3 pasireotide 2 lanreotide 2 surufatinib 1 lutetium Lu 177 dotatate 1 gadoteridol 1 gadoterate meglumine 1 gadolinium ethoxybenzyl DTPA 1 gadodiamide 1 gadobutrol 1 gadobenic acid 1 arginyllysine 1 Surveys and Questionnaires 1 Sunitinib 1 Somatostatin 1 Neuropsychological Tests 1 Magnetic Resonance Spectroscopy 1 Diazoxide 1 Cabergoline 1 64Cu-DOTATATE 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07272512 2025-12-19

ZSPAC-17

Shanghai Zhongshan Hospital

Phase 4 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡